Teleman Dan Benjamin 4

What Happened

Teleman Dan Benjamin, CEO of Nasus Pharma Ltd (NSRX), purchased 2,900 ordinary shares in an open-market transaction on April 22, 2026 at $3.76 per share, for a total of $10,904. This was a purchase (code P), which investors often view as a more informative, potentially bullish signal than routine sales.

Key Details

• Transaction date and price: 2026-04-22 — 2,900 shares at $3.76 each (total $10,904).
• Transaction type: Purchase (coded P in the Form 4).
• Shares owned after transaction: 27,046 ordinary shares beneficially owned (24,146 previously reported + 2,900 purchased).
• Additional potential shares: 132,845 Ordinary Shares issuable upon exercise of outstanding options exercisable within 60 days (per footnote).
• Filing timeliness: Report filed 2026-04-22 for the 2026-04-22 transaction (no late filing indicated).
• No 10b5-1 plan, cashless exercise, tax-withholding, or gift noted in this filing.

Context

The footnote states the reported beneficial ownership includes 24,146 ordinary shares and 132,845 shares issuable upon exercise of options that are exercisable within 60 days — those exercisable options are treated as potentially beneficially owned for reporting purposes. This filing documents a straightforward open-market purchase by the CEO; it does not disclose any subsequent sale or exercise activity.